Qiagen (NYSE:QGEN) Updates FY 2026 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 2.500- for the period, compared to the consensus estimate of 2.630. The company issued revenue guidance of $2.2 billion-, compared to the consensus revenue estimate of $2.2 billion. Qiagen also updated its Q1 2026 guidance to 0.540- EPS.

Qiagen Price Performance

Shares of Qiagen stock traded down $0.10 during trading on Wednesday, hitting $51.79. The stock had a trading volume of 2,381,654 shares, compared to its average volume of 3,079,245. Qiagen has a fifty-two week low of $39.61 and a fifty-two week high of $57.81. The business has a fifty day moving average of $49.60 and a two-hundred day moving average of $49.64. The firm has a market cap of $10.94 billion, a P/E ratio of 26.74, a PEG ratio of 2.49 and a beta of 0.67. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.60 and a quick ratio of 2.30.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.59 by $0.03. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. On average, sell-side analysts expect that Qiagen will post 2.26 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on QGEN shares. Wall Street Zen downgraded Qiagen from a “buy” rating to a “hold” rating in a research report on Saturday, January 10th. Citigroup downgraded shares of Qiagen from a “buy” rating to a “neutral” rating and lowered their target price for the company from $57.89 to $52.63 in a report on Thursday, December 11th. Deutsche Bank Aktiengesellschaft lowered Qiagen from a “buy” rating to a “hold” rating and boosted their price objective for the company from $52.00 to $54.00 in a research note on Thursday, January 22nd. Barclays reiterated an “overweight” rating and set a $57.89 price objective (up from $55.79) on shares of Qiagen in a research report on Monday, December 15th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $53.04.

Institutional Trading of Qiagen

Hedge funds and other institutional investors have recently made changes to their positions in the company. Amundi increased its stake in shares of Qiagen by 4.4% in the third quarter. Amundi now owns 4,290,273 shares of the company’s stock worth $201,471,000 after buying an additional 181,509 shares during the last quarter. Boston Partners acquired a new position in Qiagen during the 3rd quarter valued at about $179,450,000. Sei Investments Co. boosted its position in Qiagen by 5.0% during the 3rd quarter. Sei Investments Co. now owns 1,902,296 shares of the company’s stock worth $84,995,000 after acquiring an additional 90,294 shares during the period. Dimensional Fund Advisors LP bought a new position in shares of Qiagen in the third quarter valued at approximately $58,079,000. Finally, Invesco Ltd. grew its holdings in Qiagen by 29.1% during the third quarter. Invesco Ltd. now owns 1,298,776 shares of the company’s stock worth $58,029,000 after acquiring an additional 292,751 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.